Novo Nordisk submitted CagriSema to the FDA for weight management in December 2025
Arbaclofen, the R-enantiomer of baclofen, has been shown to significantly reduce repetitive grooming behaviors in Fmr1 knockout mice following acute injection, and systemic treatment improved sensory filtering abilities in Cntnap2 knockout rats, suppressing excessive acoustic startle responses (146)
Despite the negative outcomes of these studies, edaravone (Radicava), was recently approved by the USFDA (Takei et al., 2017b
It is important to note that the aforementioned study, while encouraging, does not reach the level of a noninferiority study, a trial in which an experimental treatment is compared with the standard of care, to determine whether the experimental treatment is at least as beneficial as established therapies
Neither IGF-1 LR3 nor IGF-1 DES is approved by the FDA for human or veterinary use